Data Integrity and ALCOA+ Principles in AI-Driven Regulatory Submissions

Anisha Nalwade; Rupali Waghmode; Arti Dagadkhair; Sayali Nanware; Gauri Patil; Rajendra Patil

doi:10.5281/zenodo.21806708

Review Paper | Open Access
Volume 02 | Issue 08 | Article Id IJMPS/260207137

Data Integrity and ALCOA+ Principles in AI-Driven Regulatory Submissions
Anisha Nalwade* ¹ Rupali Waghmode ¹ Arti Dagadkhair ¹ Sayali Nanware ² Gauri Patil ³ Rajendra Patil ⁴
¹Department of Regulatory Affairs, Student of Delonix Society's Baramati College of pharmacy, Barhanpur, Maharashtra, India.
²Guide, Department of Regulatory Affairs, Asst. Prof. at Delonix Society's Baramati College of pharmacy, Barhanpur, Maharashtra, India.
³Head of Department of Regulatory Affairs, Delonix Society’s Baramati College of Pharmacy, Barhanpur, Maharashtra, India.
⁴Principal, Delonix Society’s Baramati College of Pharmacy, Barhanpur, Maharashtra, India

Abstract

Artificial Intelligence (AI) is transforming pharmaceutical regulatory affairs by enhancing the efficiency, accuracy, and speed of regulatory submissions through technologies such as Machine Learning (ML), Natural Language Processing (NLP), Generative AI, and Robotic Process Automation (RPA). Despite these advancements, the successful adoption of AI depends on maintaining data integrity, which ensures that regulatory data remain accurate, complete, consistent, reliable, and traceable throughout the data lifecycle. This review discusses the importance of ALCOA+ principles—Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available—as the foundation for preserving data integrity in AI-driven regulatory submissions. It highlights AI applications in data collection, eCTD publishing, regulatory intelligence, document authoring, and lifecycle management, while addressing challenges such as poor data quality, AI hallucinations, metadata integrity, audit trail deficiencies, version control, cybersecurity, and human oversight. The review further summarizes global regulatory expectations and emphasizes the need for risk-based validation, explainable AI (XAI), robust governance frameworks, and Human-in-the-Loop (HITL) approaches to ensure transparency, accountability, and regulatory compliance. Integrating AI with ALCOA+ principles strengthens data integrity, improves submission quality, enhances inspection readiness, and supports reliable regulatory decision-making across the pharmaceutical product lifecycle.

Keywords

Dossier, Electronic submission, Natural Language Processing, Machine Learning , Optical Character Recognition, data governance , Electronic Common Technical Document (ectd) , Explainable Artificial Intelligence (XAI).

Introduction

The pharmaceutical industry is undergoing a period of rapid transformation driven by advances in genomic science, digital health technologies, informatics, and a deeper understanding of disease biology. Over the past few decades, these developments have enabled the discovery of innovative therapies that significantly improve patient outcomes.^[1]The use of novel evidence sources like real-world data and digital biomarkers is enhancing clinical evidence generation and supporting patient-centered drug development. Decentralized clinical trial methodologies using remote monitoring are alleviating patient burdens and improving efficiency. With pharmaceutical R&D becoming more data-driven, regulatory systems must adapt to manage and assess new scientific evidence, necessitating the modernization of regulatory submissions and review processes to foster innovation and ensure timely access to safe medicines.^[2]

1.1 Overview of Regulatory Submissions

Regulatory submissions are vital for the approval of pharmaceutical products, providing essential evidence of quality, safety, and efficacy to regulatory authorities. Utilizing standardized formats like the Common Technical Document (CTD) and Electronic Common Technical Document (eCTD), these submissions facilitate efficient information exchange and multidisciplinary review. They form the basis for marketing authorization applications and ensure compliance and transparency throughout the product lifecycle, ultimately speeding up patient access to safe medicines.^[1] Traditionally, pharmaceutical dossiers were cumbersome, paper-based, and prone to errors, prompting the ICH to standardize submissions through the CTD. Despite improvements, challenges in review timelines and data management persisted as drug development grew more complex and globalized.^[2]

1.2 Digital Transformation in Regulatory Affairs

The shift from paper Common Technical Document (CTD) to Electronic Common Technical Document (eCTD) in the pharmaceutical industry arises from the complexities of drug development and the need for rapid global submissions.^[3] The eCTD enhances traceability, data management, and digital submissions, facilitates international standardization, reduces manual submission errors, and allows for automated validation tests by regulatory bodies. It encompasses lifecycle management tools essential for maintaining compliance during product updates.^[4]
The evolution of eCTD comprises three stages:

1. Paper CTD Era: Initial submissions were manual, time-consuming, and error-prone.^[5,6]
2. Introduction of Electronic Submissions: In the early 2000s, various electronic formats were accepted, improving efficiency but suffering from inconsistencies.
3. Adoption of eCTD Standards: The ICH initiated eCTD standards to standardize electronic submissions, culminating in the current eCTD versions that optimize compliance and regulatory processes.^[7]

1.3 Emergence of Artificial Intelligence in Regulatory Operations

Artificial Intelligence (AI) and its subsets, including Machine Learning (ML) and Natural Language Processing (NLP), are transforming the pharmaceutical regulatory environment by automating traditional processes such as document preparation and compliance monitoring^[8,9]. AI enhances efficiency, accuracy, and speed in regulatory operations, allowing for improved data extraction, auditing, and quality management.^[10] Current applications in regulatory submissions include automated data extraction, document authoring, and quality checks, significantly reducing manual efforts and errors while enabling faster and more consistent submissions. AI-driven decision support systems also provide predictive insights, helping regulatory professionals enhance compliance and decision-making.^[11]

2. Fundamentals of Data Integrity

2.1 Definition of Data Integrity

According to WHO "Data integrity is the degree to which data are complete, consistent, accurate, trustworthy and reliable and that these characteristics of the data are maintained throughout the data life cycle. The data should be collected and maintained in a secure manner, such that they are attributable, legible, contemporaneously recorded, original or a true copy and accurate. Assuring data integrity requires appropriate quality and risk management systems, including adherence to sound scientific principles and good documentation practices." ^[13]

2.2 Importance in Pharmaceutical Regulatory Affairs

Data integrity is fundamental in pharmaceutical regulatory affairs, ensuring that data remain complete, consistent, reliable, and traceable throughout the product lifecycle. Regulatory agencies such as the FDA and EMA require compliance with data integrity principles to support product safety, efficacy, and quality while preventing regulatory actions and delays. With increasing use of electronic systems and AI, adherence to ALCOA+ principles is essential to maintain data authenticity, regulatory compliance, and patient safety^{. [12,14–16]}

2.3 Data Lifecycle in Regulatory Submissions

The data lifecycle encompasses all stages through which data pass during their existence, including generation, recording, processing, review, approval, archival, retrieval, and eventual destruction. In pharmaceutical regulatory submissions, maintaining data integrity throughout these stages is essential to ensure compliance with regulatory requirements and support reliable decision-making. Data integrity must be preserved throughout the lifecycle to guarantee that data remain accurate, consistent, complete, and available for regulatory review.^[16]

Data generation
Review
Approval
Archival
Retrieval

3. ALCOA and ALCOA+ Principles

3.1 Evolution of ALCOA Concept

Data integrity in the pharmaceutical industry evolved from paper-based records before the 1980s to electronic systems and LIMS in the 1980s–1990s, improving efficiency but introducing new security challenges. The implementation of 21 CFR Part 11 (1997) established requirements for electronic records and signatures, while later FDA, WHO, and MHRA guidelines strengthened lifecycle data governance. Since 2020, cloud platforms, electronic batch records, and automation have further improved data traceability, security, and regulatory compliance.^[17]

3.2 ALCOA Principles

Data integrity must guarantee that records are:
(i) authentic, unchangeable, and transparent—that is, the data cannot be erased;

(ii) traceable or auditable—that is, all data must have audit trails; and

(iii) safe—that is, the data is shielded from corruption and illegal access.

As a result, data must be gathered and stored securely so that it is:

Attributable to the person generating the data
Legible and permanent
Contemporaneous – data is created/recorded when the activity is performed
Original record (or ‘true copy’)
Accurate

These traits are commonly referred to as the ALCOA principles. Data integrity in the pharmaceutical sector is guaranteed by the ALCOA principles.^[18]

A. Attributable

The Attributable principle ensures that every data entry or activity can be clearly linked to the individual who performed it. Attribution may be established through initials, a full handwritten signature, a personal seal, the date, and when necessary, the time of the activity. The use of personal seals requires additional risk-management controls, including handwritten dates, restricted access, and secure storage of the seal to prevent unauthorized use. These measures ensure accountability and traceability of all recorded activities.

B. Legible, Traceable, and Permanent

The Legible, Traceable, and Permanent principle ensures that records remain readable, durable, and auditable throughout their lifecycle. Controls include the use of permanent or indelible ink, prohibition of pencil entries and erasures, documentation of corrections through single-line cross-outs with the recorder’s name, date, and reason, and avoidance of correction fluids that obscure original information. Additional controls include the use of controlled bound notebooks with sequentially numbered pages, numbered blank forms, secure archival systems, and materials that resist fading over time. These practices preserve record integrity and facilitate traceability.

C. Contemporaneous

The Contemporaneous principle requires that data be recorded at the time the activity is performed. Compliance is supported through documented procedures, personnel training, audits, and self-inspections that emphasize real-time recording in authorized documents. Records should include the date and, where applicable, the time of the activity. Well-designed documents and readily available controlled forms promote timely documentation. Furthermore, synchronized and secure time sources should be used to ensure accurate time recording, particularly for time-sensitive activities.

D. Original

The Original principle requires the preservation, review, and retention of original records or verified true copies. Organizations adopting electronic systems must ensure that reviews and approvals are conducted on original records and that any modifications are appropriately documented, justified, and traceable. Reviewer and approver signatures demonstrate accountability, while procedures should define actions for addressing errors or omissions. Secure storage controls include controlled archives, independent archivists, indexed retrieval systems, periodic retrieval testing, and appropriate reading equipment for archived formats such as microfilm. When creating true copies, organizations must verify that the copies accurately preserve the content, meaning, and format of the original records and document this verification. Particular attention should be given to maintaining the integrity of handwritten signatures and ensuring complete traceability throughout the record lifecycle.

E. Accurate

The Accurate principle ensures that data are complete, correct, and reflective of actual observations. Accuracy is maintained through regular validation of analytical methods, routine validation of production processes, and systematic review of Good Documentation Practice (GDP) records. These controls help detect and prevent errors, ensuring that recorded information remains reliable, scientifically valid, and suitable for regulatory and quality-related decision-making.^[19]

Fig. 1 ALCOA and ALCOA+ Principles.

3.3 ALCOA+ Extensions

Complete

All pertinent information should be included in the data. Analysis and decision-making might be hampered by missing data.
Example: To provide a thorough understanding of the procedure and experiment, records should contain all pertinent information. Incomplete or missing data might cause the results to be interpreted incorrectly.

Consistent

Data uniformity across many records and systems is ensured by consistency. Errors and misunderstanding can result from inconsistencies. For instance, standardized protocols must to be adhered to uniformly throughout various studies or operations. Consistency ensures reliability and comparability of data over time

Enduring

Data need to be durable and maintain its integrity throughout time. Archiving, backup, and proper storage are always seen as crucial.

Available

Data must be accessible for validation, inspection, and review. Transparency and compliance depend on accessibility. Both digital and paper records must be readily available for inspections and investigations for the duration of the record. Both paper and electronic materials should have appropriate labelling and/or clear indexing to facilitate retrieval.^[20]

4. AI Technologies Used in Regulatory Submissions

4.1 Artificial Intelligence in Regulatory Affairs

AI is transforming pharmaceutical regulatory affairs by automating routine tasks, analysing large datasets, and improving decision-making, accuracy, and efficiency. It enhances regulatory compliance, risk assessment, post-market surveillance, and stakeholder communication, enabling faster product approvals and improved patient safety.^[21]

4.2 Machine Learning Applications

Machine learning (ML) is a branch of AI that enables computers to learn from data and make predictions or decisions without explicit programming. Using supervised, unsupervised, and reinforcement learning, ML analyses large datasets to identify patterns, optimize clinical trial design, detect adverse events, support regulatory decision-making, accelerate drug development, and improve patient safety.

4.3 Natural Language Processing (NLP)

Natural Language Processing (NLP) enables the analysis of unstructured text such as clinical trial reports, regulatory documents, and scientific literature. It extracts key information, summarizes lengthy reports, identifies adverse events and safety signals, and monitors social media for real-world drug safety insights, improving data analysis and supporting informed regulatory decision-making^{. [22]}

4.4 Generative AI in Document Authoring

AI-driven document management systems automate the creation, categorization, and submission of regulatory documents using standardized templates. This improves consistency, reduces errors, enhances operational efficiency, minimizes compliance risks, and accelerates regulatory review and approval timelines.

4.5 Robotic Process Automation (RPA)

Although Robotic Process Automation (RPA) is not specifically mentioned, the article describes AI-driven process automation for document categorization, template creation, compliance monitoring, and administrative support. AI-powered assistants and chatbots improve operational efficiency, reduce manual effort, and support regulatory compliance.

4.6 AI-Enabled Regulatory Information Management Systems

AI-enabled information management in regulatory affairs automates document management, compliance tracking, real-time monitoring, and advanced data analytics. These systems standardize submissions, categorize documents, monitor reporting deadlines, detect safety signals, support post-market surveillance, and strengthen data management and regulatory decision-making.^[9]

5. AI-Driven Regulatory Submission Process

5.1 Data Collection and Compilation

Data collection for AI-driven regulatory submissions involves information from clinical trial protocols, case report forms (CRFs), patient narratives, and medical literature, much of which is unstructured and requires extensive manual processing.^[23]AI technologies such as Natural Language Processing (NLP), Machine Learning (ML), and Optical Character Recognition (OCR) automate data extraction and standardization, while Human-in-the-Loop (HITL) frameworks ensure human oversight. Transformer-based NLP extracts key clinical information, OCR converts scanned documents into machine-readable text, and confidence scoring flags uncertain data for human review, improving data quality, efficiency, and regulatory compliance.^[24]

5.2 eETD Publishing and Validation

The Electronic Common Technical Document (eCTD) is the internationally accepted format for electronic regulatory submissions to health authorities. The FDA requires eCTD for NDA, ANDA, BLA, commercial IND, and related submissions. eCTD standardizes information into Modules 1–5, supporting efficient review, lifecycle management, archiving, and retrieval. Currently, eCTD Versions 3.2.2 and 4.0 (HL7 RPS-based) are supported for improved interoperability and lifecycle management.^[25,26]

eCTD Publishing Workflow ^[2,27]

eCTD Validation Check

Validation is a critical pre-submission step that ensures technical acceptability and regulatory compliance. The FDA requires submissions to pass validation checks, including XML backbone, checksum integrity, folder structure, file naming, PDF compliance, hyperlinks, metadata, sequence numbering, and submission completeness. Failure to meet these requirements may result in rejection of the submission package.^[28] Major eCTD Validation Checks include XML backbone, folder structure, file naming, PDF specifications, hyperlinks and bookmarks, checksum integrity, metadata, sequence numbering, lifecycle operations, and submission completeness^{. [29]}

5.3 Intelligence and Gap Analysis

Regulatory Intelligence (RI) uses AI and Machine Learning to systematically collect and analyze regulatory information, enabling proactive compliance, risk management, and lifecycle decision-making. It supports impact assessment by evaluating regulatory changes, identifying trends, predicting regulatory requirements, and improving submission quality, inspection readiness, and timely regulatory approvals. From a data integrity perspective, AI-enabled RI upholds ALCOA+ principles—ensuring that regulatory information is Accurate, Contemporaneous, Complete, and Consistent. Automated systems continuously capture updates, while centralized platforms ensure the secure storage and retrieval of data, improving the reliability of regulatory submissions. Ultimately, RI is vital for maintaining compliance and submission quality in increasingly complex global regulatory landscapes.^{[4,5,11,30,31]}

5.4 Submission Tracking and Lifecycle Management

Over the course of a pharmaceutical product's lifespan, regulatory filings continue to change. Continuous management and oversight are necessary for tasks including modifications, renewals, yearly reports, safety updates, and post-approval obligations.AI-enabled lifecycle management systems provide enhanced visibility into these activities and support proactive regulatory oversight.

To support ALCOA+ compliance, lifecycle management systems should maintain:

Comprehensive audit trails.
Change history documentation.
Metadata integrity.
User accountability.
Long-term record preservation.

These controls ensure traceability throughout the submission lifecycle and support regulatory inspection readiness.

5.5 AI-Assisted Health Authority Responses

During regulatory review, health authorities often issue requests for information, deficiency letters, and clarification questions that require rapid access to relevant data and coordination among stakeholders. AI supports information retrieval, response drafting, knowledge reuse, and response quality assessment, improving efficiency. However, scientific accuracy, regulatory strategy, final approval, and submission accountability remain the responsibility of qualified regulatory professionals, and all AI-assisted responses must be reviewed before submission.

6. Data Integrity Risks in AI-Driven Regulatory Submissions

Artificial intelligence has improved regulatory operations through enhanced document preparation, data extraction, lifecycle management, and submission quality. However, AI-generated outputs require proper governance, validation, and human oversight to comply with ALCOA+ principles. Regulatory agencies emphasize that AI-generated data must remain attributable, accurate, complete, contemporaneous, consistent, enduring, available, and traceable to ensure data integrity, regulatory compliance, and reliable decision-making.^[32]

6.1 Data Quality Issues

High-quality input data are essential for trustworthy AI systems, as AI models learn from historical datasets. Incomplete, inconsistent, duplicated, outdated, or biased data can produce unreliable outputs, leading to errors in clinical data extraction, adverse event classification, metadata generation, and regulatory dossier preparation. From the perspective of ALCOA+, poor-quality data primarily violate the principles of Accuracy, Completeness, Consistency, and Originality. Since AI cannot distinguish between correct and incorrect source information without appropriate validation, data quality assessment should include automated quality checks, standardized vocabularies, source verification, and routine data governance before AI processing. Regulatory agencies therefore recommend implementing comprehensive data governance frameworks that ensure reliable source data before AI deployment.^[32]